MOTS-c — Research Dossier
Evidence grading
Structure
16-aa, mtDNA
Encoded in mitochondrial 12S rRNA; mitochondrial-derived peptide (MDP) family
Primary pathway
AMPK
Improves insulin sensitivity; upregulates GLUT4; exercise-induced in humans
Human evidence
Early / mixed
Observational/associative only; no controlled human efficacy trials
FDA approval
None
Described as experimental; research-use-only
MOTS-c has become the headline "exercise-mimetic" of the longevity space on the strength of genuinely novel preclinical data — but the human evidence does not yet support the marketing, and the important human association data shows context-dependent rather than consistent metabolic benefit.
MOTS-c (Mitochondrial ORF of the 12S rRNA type-c) is a 16-amino-acid peptide encoded within the mitochondrial genome rather than nuclear DNA — a member of the mitochondrial-derived peptide (MDP) family alongside humanin and SHLP2. It was identified by Lee and colleagues at USC (Cohen lab) in 2015, establishing mitochondria as signalling units that communicate with distant tissues via peptides.
MOTS-c is itself exercise-induced: physical activity raises endogenous MOTS-c in human muscle and circulation. "Mimics exercise" should not be read as "replaces exercise" — the two have overlapping but distinct physiological effects, and exogenous MOTS-c administration has not been tested in controlled human efficacy trials.
“Late-life intermittent MOTS-c treatment increased healthspan in mice — but exogenous administration has not been tested in controlled human efficacy trials, and the key human association data shows metabolic benefit in lean but not obese individuals, the population most likely to use it.”
— Reynolds/Lee et al., Nat Commun 2021; Cataldo et al., 2023
Mechanism
MOTS-c regulates metabolic homeostasis primarily via AMPK activation, improving insulin sensitivity and upregulating GLUT4 to enhance skeletal-muscle glucose uptake. Under metabolic stress it can translocate to the nucleus and influence nuclear gene expression — a retrograde mitochondria-to-nucleus signal that represents a novel communication axis.
It is exercise-induced: physical activity raises endogenous MOTS-c in human muscle and circulation. This makes it interesting as a potential exercise-response mediator, but also complicates the interpretation of association studies in active versus sedentary cohorts.
Evidence base
Animal data (strong, consistent)
Lee et al. (2015, Cell Metab 21:443-454) showed MOTS-c improved insulin sensitivity and reduced diet-induced obesity and insulin resistance; hyperinsulinaemic-euglycaemic clamp work showed approximately 30% improvement in glucose infusion rate. Reynolds/Lee et al. (2021, Nat Commun) showed MOTS-c enhanced physical performance in young, middle-aged, and old mice and that late-life intermittent treatment increased healthspan. Kim et al. (2019) and cardiac and T2D model data add metabolic and mitochondrial-respiration evidence.
Human data (early, mixed — the key caveat)
Exogenous MOTS-c administration has not been tested in controlled human efficacy trials. Observational data are context-dependent: Cataldo et al. (2023) found plasma MOTS-c associated with insulin sensitivity in lean but not obese individuals, and circulating levels do not map cleanly onto "better metabolism" across studies. The claim that exogenous MOTS-c mimics exercise should be treated as a hypothesis supported by animal data, not an established human finding.
Regulatory status
Not approved by the FDA, MHRA, or EMA. Described by anti-doping and medical sources as experimental. Material supplied for laboratory work is research-use-only. Evidence grade: preclinical — a novel, well-supported animal mechanism (AMPK, exercise-mimetic, healthspan) with no controlled human efficacy data and inconsistent human association data.
Nexyra Lab Catalogue
This dossier covers published clinical research on MOTS-c. Nexyra Lab supplies research-grade MOTS-c for in vitro laboratory use.
View MOTS-c in the Nexyra catalogue (research use only) →See also
References
- 1
Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance Cell Metab 2015.
- 2
Reynolds JC, Lee C, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis Nat Commun 2021.
- 3
Kim SJ, et al. The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity Physiol Rep 2019.
- 4
Cataldo LR, et al. Plasma MOTS-c levels are associated with insulin sensitivity in lean but not obese individuals Diabetes Obes Metab 2023.
Research & Laboratory Use Only
This dossier is compiled for research planning and educational purposes only. It summarises published scientific literature and does not constitute medical advice, dosing guidance, or a therapeutic claim. All Nexyra Lab products are for research purposes only and are not for human or veterinary use. Nothing in this document should be interpreted as recommending, endorsing, or facilitating the self-administration of any compound.
A one-time legal review of this template and disclaimer is recommended before the Journal section is made publicly accessible, given the health-adjacent nature of this content.
